78 related articles for article (PubMed ID: 19781565)
1. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).
Torii Y; Takahashi M; Ishida S; Goto Y; Nakahira S; Harakawa T; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2010; 55(2-3):662-5. PubMed ID: 19781565
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.
Torii Y; Goto Y; Takahashi M; Ishida S; Harakawa T; Sakamoto T; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2010; 55(2-3):407-14. PubMed ID: 19778548
[TBL] [Abstract][Full Text] [Related]
3. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.
Kim SH; Kim SB; Yang GH; Rhee CH
Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats.
Sakamoto T; Torii Y; Takahashi M; Ishida S; Goto Y; Nakano H; Harakawa T; Ginnaga A; Kozaki S; Kaji R
Toxicon; 2009 Nov; 54(6):857-61. PubMed ID: 19559720
[TBL] [Abstract][Full Text] [Related]
5. Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.
Torii Y; Goto Y; Nakahira S; Ginnaga A
Toxicon; 2014 Nov; 90():97-105. PubMed ID: 25110177
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
Chung ME; Song DH; Park JH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
[TBL] [Abstract][Full Text] [Related]
7. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model.
Cichon JV; McCaffrey TV; Litchy WJ; Knops JL
Laryngoscope; 1995 Feb; 105(2):144-8. PubMed ID: 8544593
[TBL] [Abstract][Full Text] [Related]
8. Production of polyclonal antibodies in mice against cobratoxin, botulinum toxin and ricin without altering their toxicity or use of adjuvant.
Lipps BV
J Nat Toxins; 2001 Feb; 10(1):27-32. PubMed ID: 11288726
[TBL] [Abstract][Full Text] [Related]
9. In vitro assays for botulinum toxin and antitoxins.
Shone C; Appleton N; Wilton-Smith P; Hambleton P; Modi N; Gatley S; Melling J
Dev Biol Stand; 1986; 64():141-5. PubMed ID: 3792644
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
Dressler D
Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
[TBL] [Abstract][Full Text] [Related]
11. Clostridium botulinum subtype Ba.
Giménez DF
Zentralbl Bakteriol Mikrobiol Hyg A; 1984 May; 257(1):68-72. PubMed ID: 6380157
[TBL] [Abstract][Full Text] [Related]
12. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
Greene PE; Fahn S
Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
[TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies against botulinum toxins.
Sesardic D; Jones RG; Leung T; Alsop T; Tierney R
Mov Disord; 2004 Mar; 19 Suppl 8():S85-91. PubMed ID: 15027059
[TBL] [Abstract][Full Text] [Related]
14. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids.
Gupta RK; Siber GR
Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950
[TBL] [Abstract][Full Text] [Related]
15. Extensor digitorum brevis test and resistance to botulinum toxin type A.
Gordon PH; Gooch CL; Greene PE
Muscle Nerve; 2002 Dec; 26(6):828-31. PubMed ID: 12451609
[TBL] [Abstract][Full Text] [Related]
16. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
[TBL] [Abstract][Full Text] [Related]
17. Measurement of botulinum toxin activity: evaluation of the lethality assay.
Pearce LB; Borodic GE; First ER; MacCallum RD
Toxicol Appl Pharmacol; 1994 Sep; 128(1):69-77. PubMed ID: 8079356
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study.
Smuts JA; Schultz D; Barnard A
Headache; 2004 Sep; 44(8):801-5. PubMed ID: 15330827
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity.
Kutschenko A; Reinert MC; Klinker F; Paulus W; Hesse S; Liebetanz D
Muscle Nerve; 2011 Dec; 44(6):930-6. PubMed ID: 22102464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
